NYSE:LLY - Eli Lilly and Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $317.00
Forecasted Upside: 3.42 %
Number of Analysts: 17
Breakdown:
0 Sell Ratings
3 Hold Ratings
14 Buy Ratings
0 Strong Buy Ratings

^$306.53 As of 08/9/2022 10:46 AM ET

▲ +4.03 (1.33%)

1 month | 3 months | 12 months

Get New Eli Lilly and Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

^$317.00

▲ +3.42% Upside Potential

This price target is based on 17 analysts offering 12 month price targets for Eli Lilly and in the last 3 months. The average price target is $317.00, with a high forecast of $395.00 and a low forecast of $264.00. The average price target represents a 3.42% upside from the last price of $306.53.

Current Consensus is Buy

The current consensus among 17 investment analysts is to buy stock in Eli Lilly and. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/15/2021

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/16/2021

0 strong buy ratings
12 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/14/2021

0 strong buy ratings
13 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/12/2021

0 strong buy ratings
13 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/10/2022

0 strong buy ratings
14 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/11/2022

0 strong buy ratings
14 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/10/2022

0 strong buy ratings
15 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

8/9/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/27/2022	UBS Group	Boost Price Target	Outperform	$335.00	Low
7/8/2022	Morgan Stanley	Boost Price Target	Overweight	$369.00 ➝ $395.00	N/A
7/7/2022	Barclays	Boost Price Target	Overweight	$333.00 ➝ $355.00	N/A
6/1/2022	JPMorgan Chase & Co.	Boost Price Target		$340.00 ➝ $355.00	Low
5/23/2022	SVB Leerink	Initiated Coverage	Outperform	$341.00	Low
5/2/2022	Mizuho	Boost Price Target		$315.00 ➝ $356.00	Low
4/29/2022	Morgan Stanley	Boost Price Target		$364.00 ➝ $369.00	High
4/29/2022	Wells Fargo & Company	Boost Price Target		$280.00 ➝ $305.00	Medium
4/12/2022	The Goldman Sachs Group	Boost Price Target	Neutral	$234.00 ➝ $264.00	Low
4/6/2022	Morgan Stanley	Boost Price Target	Overweight	$265.00 ➝ $364.00	High
3/17/2022	Bank of America	Boost Price Target		$300.00 ➝ $315.00	Medium
3/10/2022	Daiwa Capital Markets	Initiated Coverage	Outperform	$286.00	Medium
2/4/2022	Mizuho	Lower Price Target	Buy	$302.00 ➝ $293.00	High
2/4/2022	Morgan Stanley	Lower Price Target	Overweight	$272.00 ➝ $265.00	Medium
1/24/2022	Morgan Stanley	Lower Price Target	Overweight	$275.00 ➝ $272.00	Low
1/21/2022	DZ Bank	Upgrade	Hold ➝ Buy	$291.00	Medium
1/5/2022	Mizuho	Boost Price Target		$272.00 ➝ $302.00	High
1/4/2022	Wells Fargo & Company	Boost Price Target	Equal Weight	$270.00 ➝ $280.00	Low
1/3/2022	Sanford C. Bernstein	Boost Price Target	Market Perform	$250.00 ➝ $300.00	High
12/20/2021	Berenberg Bank	Boost Price Target	Buy	$270.00 ➝ $305.00	High
12/20/2021	Barclays	Boost Price Target	Overweight	$280.00 ➝ $325.00	High
12/17/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$236.00	High
12/16/2021	Mizuho	Initiated Coverage	Buy	$272.00	Low
12/16/2021	BMO Capital Markets	Boost Price Target	Outperform	$311.00 ➝ $320.00	Low
12/16/2021	Bank of America	Boost Price Target	Buy	$285.00 ➝ $300.00	Low
12/16/2021	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
12/8/2021	Wells Fargo & Company	Initiated Coverage	Equal Weight	$270.00	Low
11/24/2021	Truist Financial	Boost Price Target	Buy	$262.00 ➝ $301.00	Low
11/18/2021	BMO Capital Markets	Initiated Coverage	Outperform	$311.00	Medium
10/27/2021	Mizuho	Lower Price Target	Buy	$279.00 ➝ $272.00	Low
10/11/2021	Berenberg Bank	Upgrade	Hold ➝ Buy	$240.00 ➝ $270.00	Low
9/29/2021	Citigroup	Upgrade	Neutral ➝ Buy	$210.00 ➝ $265.00	High
9/24/2021	JPMorgan Chase & Co.	Reiterated Rating	Buy	$300.00	Low
8/30/2021	Cowen	Boost Price Target	Outperform	$250.00 ➝ $300.00	Low
8/9/2021	Argus	Boost Price Target	Buy	$225.00 ➝ $300.00	Medium
8/5/2021	DZ Bank	Upgrade	Hold ➝ Buy	$288.00	Low
8/4/2021	JPMorgan Chase & Co.	Boost Price Target	Top Pick ➝ Overweight	$270.00 ➝ $300.00	Medium
8/4/2021	Morgan Stanley	Boost Price Target	Overweight	$207.00 ➝ $275.00	High
8/4/2021	Mizuho	Boost Price Target	Buy	$250.00 ➝ $279.00	High
7/27/2021	Truist Financial	Initiated Coverage	Buy	$262.00	Low
7/7/2021	Mizuho	Reiterated Rating	Buy	$250.00	Low
7/6/2021	Barclays	Boost Price Target	Overweight	$227.00 ➝ $250.00	Low
7/2/2021	Truist Financial	Boost Price Target	Buy ➝ Buy	$225.00 ➝ $262.00	Low
6/24/2021	Cantor Fitzgerald	Boost Price Target	Positive ➝ Overweight	$245.00 ➝ $300.00	High
6/24/2021	Cowen	Boost Price Target	Positive ➝ Outperform	$235.00 ➝ $250.00	High
6/15/2021	JPMorgan Chase & Co.	Boost Price Target	Overweight	$240.00 ➝ $260.00	Low
6/14/2021	The Goldman Sachs Group	Boost Price Target	Positive ➝ Conviction-Buy	$252.00 ➝ $270.00	Low
6/8/2021	Truist Financial	Reiterated Rating	Buy	$225.00	Medium
4/28/2021	Morgan Stanley	Lower Price Target	Overweight	$217.00 ➝ $207.00	Medium
4/28/2021	Mizuho	Lower Price Target	Buy	$228.00 ➝ $216.00	Medium
4/28/2021	Barclays	Lower Price Target	Overweight	$232.00 ➝ $227.00	Medium
3/15/2021	Truist Financial	Boost Price Target	Buy	$215.00 ➝ $225.00	High
2/12/2021	Cowen	Boost Price Target	Outperform	$195.00 ➝ $235.00	Low
2/4/2021	Morgan Stanley	Boost Price Target	Overweight	$190.00 ➝ $217.00	Medium
2/1/2021	Truist Financial	Boost Price Target		$200.00 ➝ $215.00	Low
2/1/2021	Mizuho	Boost Price Target	Buy	$222.00 ➝ $228.00	Low
2/1/2021	Barclays	Boost Price Target	Overweight	$190.00 ➝ $232.00	Low
1/22/2021	Bank of America	Boost Price Target	Buy	$195.00 ➝ $225.00	Medium
1/19/2021	Mizuho	Upgrade	Neutral ➝ Buy	$164.00 ➝ $222.00	N/A
1/12/2021	Truist Financial	Boost Price Target		$182.00 ➝ $200.00	Medium
12/16/2020	Mizuho	Boost Price Target	Neutral	$156.00 ➝ $164.00	High
12/10/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$147.00 ➝ $183.00	Medium
11/17/2020	Mizuho	Lower Price Target	Neutral	$164.00 ➝ $156.00	Low
11/10/2020	Sanford C. Bernstein	Initiated Coverage	Market Perform	$150.00	Low
10/28/2020	Morgan Stanley	Lower Price Target	Overweight	$176.00 ➝ $170.00	Low
10/23/2020	Truist Financial	Initiated Coverage	Buy	$180.00	Medium
10/16/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$190.00 ➝ $200.00	Low
9/29/2020	Berenberg Bank	Initiated Coverage	Hold	$144.00	Medium
9/3/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$149.55 ➝ $176.00	High
8/14/2020	Morgan Stanley	Boost Price Target	Equal Weight	$148.00 ➝ $157.00	Low
6/29/2020	Mizuho	Boost Price Target	Neutral	$155.00 ➝ $164.00	Low
6/19/2020	Bank of America	Reiterated Rating	Buy	$180.00	Low
6/17/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$175.00 ➝ $190.00	Low
6/16/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$182.00	High
4/24/2020	Mizuho	Boost Price Target	Buy	$148.00 ➝ $155.00	Low
4/24/2020	Cfra	Boost Price Target	Hold	$146.00 ➝ $167.00	Low
4/24/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$156.00 ➝ $185.00	Low
4/20/2020	UBS Group	Downgrade	Buy ➝ Neutral	$157.00 ➝ $158.00	High
4/19/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low
4/15/2020	Cowen	Boost Price Target	Outperform	$145.00 ➝ $160.00	Medium
4/9/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$148.00	Low
4/2/2020	Mizuho	Reiterated Rating	Hold	$148.00	Medium
4/2/2020	Morgan Stanley	Lower Price Target	Overweight ➝ Equal Weight	$150.00 ➝ $148.00	High
3/11/2020	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$168.00	Medium
2/27/2020	Barclays	Initiated Coverage	Overweight		High
2/18/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Low
2/5/2020	Mizuho	Initiated Coverage	Neutral	$148.00	Low
2/3/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Medium
12/30/2019	Argus	Boost Price Target	Buy	$145.00 ➝ $165.00	Low
12/18/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$140.00 ➝ $150.00	High
12/18/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$116.00 ➝ $150.00	High
12/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Low
10/17/2019	UBS Group	Lower Price Target	Buy	$134.00 ➝ $133.00	Low
10/16/2019	Bank of America	Initiated Coverage	Buy	$133.00	Low
9/10/2019	Bank of America	Set Price Target	Neutral	$118.00 ➝ $120.00	High
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$135.00	Low
5/1/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $133.00	Low
4/30/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Medium
4/23/2019	Edward Jones	Upgrade	Hold ➝ Buy	$117.49	Low
4/22/2019	BMO Capital Markets	Lower Price Target	Outperform	$130.00	Medium
4/14/2019	Barclays	Reiterated Rating	Buy	$140.00	Low
4/11/2019	Guggenheim	Downgrade	Buy ➝ Neutral	$125.84	Low
3/22/2019	Credit Suisse Group	Set Price Target	Hold	$121.00	Low
3/21/2019	Bank of America	Set Price Target	Hold	$129.00	Low
3/20/2019	UBS Group	Initiated Coverage	Buy	$140.00 ➝ $74.51	Low
3/12/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$140.00	Low
2/26/2019	Citigroup	Set Price Target	Hold	$124.00	Medium
2/8/2019	UBS Group	Lower Price Target	Average	$107.53 ➝ $100.00	Low
2/4/2019	Cantor Fitzgerald	Reiterated Rating	Buy		Low
1/23/2019	UBS Group	Initiated Coverage	Buy ➝ Buy	$131.00	Low
1/20/2019	Barclays	Reiterated Rating	Buy	$130.00	Low
12/27/2018	Argus	Reiterated Rating	Buy		Medium
12/24/2018	BMO Capital Markets	Boost Price Target	Outperform	$124.00 ➝ $132.00	Low
12/20/2018	Morgan Stanley	Set Price Target	Hold	$116.00	High
12/19/2018	BMO Capital Markets	Reiterated Rating	Buy		Low
12/2/2018	Citigroup	Downgrade	Buy ➝ Neutral	$113.00	Low
11/26/2018	Citigroup	Downgrade	Buy ➝ Neutral	$115.00	Low
11/7/2018	Societe Generale	Set Price Target	Hold	$106.00	High
10/31/2018	Credit Suisse Group	Upgrade	Underperform ➝ Neutral		Medium
10/23/2018	Wolfe Research	Initiated Coverage	Market Perform	$119.00	Low
10/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$128.00	Medium
10/12/2018	Barclays	Boost Price Target	Overweight	$112.00 ➝ $120.00	Low
10/8/2018	Guggenheim	Initiated Coverage	Buy ➝ Buy		Low
10/5/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$123.00	Low
10/4/2018	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$107.00 ➝ $130.00	High
10/3/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$90.00 ➝ $107.00	Medium
10/1/2018	SunTrust Banks	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $123.00	Low
9/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$110.00	Low
9/26/2018	JPMorgan Chase & Co.	Set Price Target	Not Rated ➝ Overweight	$117.00	Low
9/18/2018	Barclays	Reiterated Rating	Overweight	$107.00 ➝ $112.00	Low
9/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$110.00	Low
9/7/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$98.00 ➝ $107.00	Medium
7/31/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $102.00	Low
7/31/2018	SunTrust Banks	Reiterated Rating	Buy	$105.00	Low
7/25/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$90.00 ➝ $94.00	Medium
7/25/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Underperform	$84.00 ➝ $86.00	High
7/25/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$80.00 ➝ $90.00	High
7/25/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $110.00	High
7/25/2018	Berenberg Bank	Downgrade	Buy ➝ Hold	$99.00	High
7/25/2018	The Goldman Sachs Group	Set Price Target	Neutral	$100.00	High
7/24/2018	Cowen	Set Price Target	Buy	$105.00	High
7/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	High
7/19/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ $89.43	$78.00 ➝ $80.00	Medium
7/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	Low
7/17/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$86.00 ➝ $90.00	Low
7/15/2018	Jefferies Financial Group	Set Price Target	Buy	$100.00	Low
7/13/2018	Credit Suisse Group	Set Price Target	Hold	$84.00	Low
7/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	Low
6/22/2018	DZ Bank	Reiterated Rating	Buy ➝ Hold		Low
6/21/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Underperform	$82.00 ➝ $84.00	Low
6/11/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$100.00	Low
6/7/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$100.00	Low
5/22/2018	Barclays	Set Price Target	Buy	$98.00	Low
5/15/2018	Credit Suisse Group	Set Price Target	Hold	$82.00	Low
5/10/2018	BMO Capital Markets	Reiterated Rating	Hold	$78.00	Low
4/25/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$79.00 ➝ $78.00	Medium
4/24/2018	BMO Capital Markets	Reiterated Rating	Hold	$79.00	Medium
4/22/2018	Credit Suisse Group	Set Price Target	Hold	$80.00	Medium
4/18/2018	HC Wainwright	Reiterated Rating	Buy		Low
4/13/2018	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$74.00 ➝ $79.00	Low
4/13/2018	Jefferies Financial Group	Set Price Target	Buy	$90.00	Low
4/4/2018	BMO Capital Markets	Reiterated Rating	Sell	$74.00	Medium
3/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$91.00	Medium
2/26/2018	Jefferies Financial Group	Set Price Target	Buy	$93.00	Low
2/26/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$105.00	Medium
2/2/2018	Credit Suisse Group	Reiterated Rating	Hold	$80.00	Low
2/1/2018	Bank of America	Lower Price Target	Neutral ➝ Neutral	$88.00 ➝ $86.00	Low
2/1/2018	BMO Capital Markets	Boost Price Target	Underperform ➝ Underperform	$73.00 ➝ $74.00	Low
1/22/2018	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$82.00	Low
1/16/2018	Jefferies Financial Group	Set Price Target	Buy	$100.00	High
1/16/2018	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$86.98 ➝ $95.00	High
1/5/2018	Argus	Upgrade	Hold ➝ Buy	$85.52 ➝ $115.00	Medium
12/13/2017	Credit Suisse Group	Reiterated Rating	Hold		Medium
12/12/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	Low
12/5/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	Low
11/21/2017	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$86.00 ➝ $90.00	N/A
11/1/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A
10/26/2017	Berenberg Bank	Reiterated Rating	Buy	$98.00	N/A
10/24/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A
10/23/2017	SVB Leerink	Boost Price Target	Market Perform	$92.00 ➝ $93.00	N/A
10/16/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A
10/13/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$105.00	N/A
10/13/2017	Barclays	Boost Price Target	Overweight	$90.00 ➝ $98.00	N/A
10/10/2017	BMO Capital Markets	Boost Price Target	Underperform	$71.00 ➝ $73.00	N/A
10/10/2017	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$84.23 ➝ $88.00	N/A
10/6/2017	Morgan Stanley	Set Price Target	Hold	$86.00	N/A
10/5/2017	The Goldman Sachs Group	Reiterated Rating	Buy	$92.00 ➝ $95.00	N/A
10/4/2017	Cowen	Reiterated Rating	Buy	$95.00	Low
9/28/2017	BMO Capital Markets	Reiterated Rating	Sell	$71.00	Low
9/15/2017	Morgan Stanley	Reiterated Rating	Hold	$86.00	Low
9/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$89.00 ➝ $89.00	Low
9/8/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$103.00 ➝ $105.00	Low
9/6/2017	BMO Capital Markets	Reiterated Rating	Underperform	$73.00 ➝ $71.00	Low
8/31/2017	Jefferies Financial Group	Reiterated Rating	Buy	$89.00	Medium
8/31/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$103.00	Low
8/31/2017	SVB Leerink	Reiterated Rating	Hold		Low
8/24/2017	Jefferies Financial Group	Reiterated Rating	Buy	$94.00 ➝ $89.00	Low
8/16/2017	BMO Capital Markets	Reiterated Rating	Sell	$73.00	High

(Data available from 8/9/2017 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

24 very positive mentions
52 positive mentions
10 negative mentions
5 very negative mentions

Mentions as of

1/11/2022

11 very positive mentions
66 positive mentions
14 negative mentions
4 very negative mentions

Mentions as of

2/10/2022

19 very positive mentions
60 positive mentions
6 negative mentions
15 very negative mentions

Mentions as of

3/12/2022

15 very positive mentions
23 positive mentions
8 negative mentions
8 very negative mentions

Mentions as of

4/11/2022

16 very positive mentions
55 positive mentions
4 negative mentions
11 very negative mentions

Mentions as of

5/11/2022

26 very positive mentions
66 positive mentions
6 negative mentions
10 very negative mentions

Mentions as of

6/10/2022

17 very positive mentions
36 positive mentions
6 negative mentions
8 very negative mentions

Mentions as of

7/10/2022

8 very positive mentions
55 positive mentions
9 negative mentions
8 very negative mentions

Mentions as of

8/9/2022

Current Sentiment

Recent Stories by Sentiment

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $306.53

$302.06

$306.53

50 Day Range

MA: $315.68

$288.07

$331.60

52 Week Range

Now: $306.53

$220.20

$335.33

Volume

3,068 shs

Average Volume

2,537,060 shs

Market Capitalization

$291.26 billion

P/E Ratio

48.89

Dividend Yield

1.30%

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and?: The following sell-side analysts have issued reports on Eli Lilly and in the last twelve months: Argus, Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Cowen Inc, Daiwa Capital Markets, DZ Bank AG, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Sanford C. Bernstein, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for LLY.
What is the current price target for Eli Lilly and?: 17 Wall Street analysts have set twelve-month price targets for Eli Lilly and in the last year. Their average twelve-month price target is $317.00, suggesting a possible upside of 3.4%. Morgan Stanley has the highest price target set, predicting LLY will reach $395.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $264.00 for Eli Lilly and in the next year.
View the latest price targets for LLY.
What is the current consensus analyst rating for Eli Lilly and?: Eli Lilly and currently has 3 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LLY will outperform the market and that investors should add to their positions of Eli Lilly and.
View the latest ratings for LLY.
What other companies compete with Eli Lilly and?: Other companies that are similar to Eli Lilly and include Pfizer, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb and Johnson & Johnson. Learn More about companies similar to Eli Lilly and.
How do I contact Eli Lilly and's investor relations team?: Eli Lilly and's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is (317) 276-2000 and its investor relations email address is [email protected] The official website for Eli Lilly and is www.lilly.com. Learn More about contacing Eli Lilly and investor relations.

NYSE:LLY - Eli Lilly and Stock Price Target and Predictions

Analyst Price Target for LLY

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.13 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and?

What is the current price target for Eli Lilly and?

What is the current consensus analyst rating for Eli Lilly and?

What other companies compete with Eli Lilly and?

How do I contact Eli Lilly and's investor relations team?